Anxiety and Somatic Symptoms in Children and Adolescents Diagnosed with Attention-Deficit Hyperactivity Disorder
This article is part of Special Issue:
Esra Okyar,
Leyla Bozatlı,
Işık Görker,
Serap Okyar,
Corresponding Author
Esra Okyar
Department of Child and Adolescent Psychiatry, Sakarya Training and Research Hospital, Sakarya, Turkey seah.gov.tr
Search for more papers by this authorLeyla Bozatlı
Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey trakya.edu.tr
Search for more papers by this authorIşık Görker
Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey trakya.edu.tr
Search for more papers by this authorSerap Okyar
Faculty of Medicine, Department of Public Health, Sakarya University, Sakarya, Turkey sakarya.edu.tr
Search for more papers by this authorEsra Okyar,
Leyla Bozatlı,
Işık Görker,
Serap Okyar,
Corresponding Author
Esra Okyar
Department of Child and Adolescent Psychiatry, Sakarya Training and Research Hospital, Sakarya, Turkey seah.gov.tr
Search for more papers by this authorLeyla Bozatlı
Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey trakya.edu.tr
Search for more papers by this authorIşık Görker
Faculty of Medicine, Department of Child and Adolescent Psychiatry, Trakya University, Edirne, Turkey trakya.edu.tr
Search for more papers by this authorSerap Okyar
Faculty of Medicine, Department of Public Health, Sakarya University, Sakarya, Turkey sakarya.edu.tr
Search for more papers by this authorAcademic Editor: Giulio Perrotta
Abstract
Background. Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition typified by inattention, hyperactivity, and impulsivity. Comorbid psychiatric disorders are common among children and adolescents with ADHD. In this study, it was aimed to examine anxiety and somatic symptoms in children and adolescents with ADHD and the effect of methylphenidate treatment on these symptoms. Method. Three groups were formed, consisting of 37 children and adolescents diagnosed with ADHD and received methylphenidate treatment, 37 newly diagnosed, treatment-naive children and adolescents with ADHD diagnosis, and 37 children and adolescents without the diagnosis of ADHD. The symptoms of ADHD in children were examined by using the DSM-IV-based child and adolescent behavior disorders screening and rating scale, the symptoms of anxiety were examined by using the screen for child anxiety-related disorders (SCARED), and somatic symptoms were examined by using the DSM-5 level 2 somatic symptom scale. Results. In the newly diagnosed, treatment-naive with ADHD group, anxiety and somatic symptoms were found to be significantly higher compared to the ADHD group with methylphenidate treatment and the non-ADHD group. It was shown that the symptoms of panic disorder, generalized anxiety, and social phobia were observed more in the newly diagnosed, treatment-naive with ADHD group compared to the treatment group with ADHD. Conclusions. It was determined that children and adolescents diagnosed with ADHD had more anxiety and somatic symptoms. Anxiety and somatic symptoms increased as the severity of ADHD symptoms increased. Anxiety and somatic symptoms were lower than in ADHD children receiving methylphenidate treatment. Clinicians should keep in mind to evaluate anxiety and somatic symptoms in children and adolescents with ADHD before the treatment.
Conflicts of Interest
The authors declare that there is no conflict of interest.
Open Research
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
- 1
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM 5), 2013, American Psychiatric Association, Washington, DC, USA, https://doi.org/10.1176/appi.books.9780890425596.
10.1176/appi.books.9780890425596 Google Scholar
- 2
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders 4th edition text revision (DSM-IV-TR), 2000, American Psychiatric Association, Washington, DC, USA.
10.1176/appi.books.9780890423349 Google Scholar
- 3 Polanczyk G., de Lima M. S., Horta B. L., Biederman J., and Rohde L. A., The worldwide prevalence of ADHD: a systematic review and metaregression analysis, American Journal of Psychiatry. (2007) 164, no. 6, 942–948.
- 4 Skounti M., Philalithis A., and Galanakis E., Variations in prevalence of attention deficit hyperactivity disorder worldwide, European Journal of Pediatrics. (2006) 166, no. 2, 117–123, https://doi.org/10.1007/s00431-006-0299-5, 2-s2.0-33845894703, 17033803.
- 5 Reale L., Bartoli B., Cartabia M., Zanetti M., Costantino M. A., Canevini M. P., Termine C., Bonati M., and on behalf of Lombardy ADHD Group, Comorbidity prevalence and treatment outcome in children and adolescents with ADHD, European Child & Adolescent Psychiatry. (2017) 26, no. 12, 1443–1457, https://doi.org/10.1007/s00787-017-1005-z, 2-s2.0-85019601334.
- 6 Jehnsen C. M. and Steinhausen H. C., Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study, ADHD Attention Deficit and Hyperactivity Disorders. (2015) 7, no. 1, 27–38, https://doi.org/10.1007/s12402-014-0142-1, 2-s2.0-84939890576.
- 7 Taurines R., Schmitt J., Renner T., Conner A. C., Warnke A., and Romanos M., Developmental comorbidity in attention-deficit/hyperactivity disorder, ADHD Attention Deficit and Hyperactivity Disorders. (2010) 2, no. 4, 267–289, https://doi.org/10.1007/s12402-010-0040-0, 2-s2.0-79960063937.
- 8 Banaschewski T., Becker K., Döpfner M., Holtmann M., Rösler M., and Romanos M., Attention-deficit/hyperactivity disorder, Deutsches Ärzteblatt International. (2017) 114, no. 9, 149–159, https://doi.org/10.3238/arztebl.2017.0149, 2-s2.0-85015765701, 28351467.
- 9 Mayes S. D., Calhoun S. L., Bixler E. O., Vgontzas A. N., Mahr F., Hillwig-Garcia J., Elamir B., Edhere-Ekezie L., and Parvin M., ADHD subtypes and comorbid anxiety, depression and oppositional-defiant disorder: differences in sleep problems, Journal of Pediatric Psychology. (2009) 34, no. 3, 328–337, https://doi.org/10.1093/jpepsy/jsn083, 2-s2.0-64949110948, 18676503.
- 10 Zablotsky B., Bramlett M. D., Visser S. N., Danielson M. L., and Blumberg S. J., Latent class analysis of ADHD neurodevelopmental and mental health comorbidities, Journal of Developmental and Behavioral Pediatrics. (2018) 39, no. 1, 10–19, https://doi.org/10.1097/DBP.0000000000000508, 2-s2.0-85048356837, 28902066.
- 11 Polanczyk G. V., Salum G. A., Sugaya L. S., Caye A., and Rohde L. A., Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents, Journal of Child Psychology and Psychiatry. (2015) 56, no. 3, 345–365, https://doi.org/10.1111/jcpp.12381, 2-s2.0-84923632321, 25649325.
- 12 Newcorn J. H., Managing ADHD and comorbidities in adults, The Journal of Clinical Psychiatry. (2009) 70, no. 2, article e40, https://doi.org/10.4088/JCP.7129br7c.e40, 2-s2.0-62649143804.
- 13 Biederman J., Monuteaux M. C., Spencer T., Wilens T. E., Macpherson H. A., and Faraone S. V., Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow up study, The American Journal of Psychiatry. (2008) 165, no. 5, 597–603, https://doi.org/10.1176/appi.ajp.2007.07091486, 2-s2.0-43949094146, 18316421.
- 14 Katzman M. A., Bilkey T. S., Chokka P. R., Fallu A., and Klassen L. J., Adult ADHD and comorbid disorders: clinical implications of a dimensional approach, BMC Psychiatry. (2017) 17, no. 1, https://doi.org/10.1186/s12888-017-1463-3, 2-s2.0-85028005388, 28830387.
- 15 D’Agati E., Curatolo P., and Mazzone L., Comorbidity between ADHD and anxiety disorders across the lifespan, International Journal of Psychiatry in Clinical Practice. (2019) 23, no. 4, 238–244, https://doi.org/10.1080/13651501.2019.1628277, 2-s2.0-85068072069, 31232613.
- 16 Reimherr F. W., Marchant B. K., Gift T. E., and Steans T. A., ADHD and anxiety: clinical significance and treatment implications, Current Psychiatry Reports. (2017) 19, no. 12, https://doi.org/10.1007/s11920-017-0859-6, 2-s2.0-85035134160.
- 17 Winding T. N. and Andersen J. H., Do negative childhood conditions increase the risk of somatic symptoms in adolescence? – A prospective cohort study, BMC Public Health. (2019) 19, no. 1, https://doi.org/10.1186/s12889-019-7198-y, 2-s2.0-85068910033.
- 18 Ghandour R. M., Overpeck M. D., Huang Z. J., Kogan M. D., and Scheidt P. C., Headache, stomachache, backache, and morning fatigue among adolescent girls in the United States: associations with behavioral, sociodemographic, and environmental factors, Archives of Pediatrics & Adolescent Medicine. (2004) 158, no. 8, 797–803, https://doi.org/10.1001/archpedi.158.8.797, 2-s2.0-3543143567, 15289254.
- 19 Giacobo R. S., Jané M. C., Bonillo A., Arrufat F. J., and Araujo E., ADHD and functional somatic symptoms: structural equations of a conceptual model, Child and Adolescent Mental Health. (2014) 19, no. 2, 83–89, https://doi.org/10.1111/camh.12026, 2-s2.0-84897496119, 32878391.
- 20 Wu S., Yang T., He Y., Cui X., Luo X., and Liu J., Association between hyperactivity symptoms and somatic complaints: mediating and moderating mechanisms in childhood trauma and life events among Chinese male adolescents, Frontiers in Psychiatry. (2021) 12, no. 12, article 630845, https://doi.org/10.3389/fpsyt.2021.630845.
- 21 Kim S. M., Min K. J., and Han D. H., Effects of methylphenidate on somatic symptoms and brain functional connectivity in adolescents with attention deficit hyperactivity disorder: a pilot study, Clinical Psychopharmacology and Neuroscience. (2022) 20, no. 2, 259–270, https://doi.org/10.9758/cpn.2022.20.2.259, 35466097.
- 22 Snircova E., Marcincakova-Husarova V., Hrtanek I., Kulhan T., Ondrejka I., and Nosalova G., Anxiety reduction on atomoxetine and methylphenidate medication in children with ADHD, Pediatrics International. (2016) 58, no. 6, 476–481, https://doi.org/10.1111/ped.12847, 2-s2.0-84976519184, 26579704.
- 23 Golubchik P., Golubchik L., Sever J. M., and Weizman A., The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety, International Clinical Psychopharmacology. (2014) 29, no. 5, 274–278, https://doi.org/10.1097/YIC.0000000000000034, 2-s2.0-84906085636.
- 24 Moshe K., Karni A., and Tirosh E., Anxiety and methylphenidate in attention deficit hyperactivity disorder: a double-blind placebo-drug trial, ADHD Attention Deficit and Hyperactivity Disorders. (2012) 4, no. 3, 153–158, https://doi.org/10.1007/s12402-012-0078-2, 2-s2.0-84865811134.
- 25 Ercan E. S., Amado S., Somer O., and Çıkoğlu S., Dikkat eksikliği hiperaktivite bozukluğu ve yıkıcı davranış bozuklukları için bir test bataryası geliştirme çalışması, Çocuk ve Gençlik Ruh Sağlığı Dergisi. (2001) 8, no. 3, 132–144.
- 26 Çakmakçı F. K., Çocuklarda Anksiyete Bozukluklarını Tarama Ölçeği geçerlik ve güvenirlik çalışması, 2004, Yayınlanmamış tıpta uzmanlık tezi, Faculty of Medicine, Kocaeli University, Kocaeli.
- 27
Sapmaz Ş. Y.,
Demirgören B. S.,
Ülker G. S., and
Aydemir Ö., Validity and reliability of the Turkish version of DSM-5 level 2 somatic symptom scale (child form for 11-17 years and parent form for 6-17 years), Anatolian Journal of Psychiatry. (2017) 18, no. 2, 114–121, https://doi.org/10.5455/apd.229979, 2-s2.0-85019190259.
10.5455/apd.229979 Google Scholar
- 28 Ulloa R. E., Sanchez S., Sauceda J. M., and Ortiz S., Psychopathology associated to attention deficit hyperactivity disorder in school age children, Actas Españolas de Psiquiatría. (2006) 34, no. 5, 330–335, 16991022.
- 29 Souza I., Pinheiro M. A., and Mattos P., Anxiety disorders in an attention-deficit/hyperactivity disorder clinical sample, Arquivos de Neuro-Psiquiatria. (2005) 63, no. 2B, 407–409, https://doi.org/10.1590/S0004-282X2005000300008, 2-s2.0-21744450887, 16059589.
- 30 Bowen R., Chavira D. A., Bailey K., Stein M. T., and Stein M. B., Nature of anxiety comorbid with attention deficit hyperactivity disorder in children from a pediatric primary care setting, Psychiatry Research. (2008) 157, no. 1-3, 201–209, https://doi.org/10.1016/j.psychres.2004.12.015, 2-s2.0-36448976551.
- 31 Mancini C., Van Ameringen M., Oakman J. M., and Figueiredo D., Childhood attention deficit/hyperactivity disorder in adults with anxiety disorders, Psychological Medicine. (1999) 29, no. 3, 515–525, https://doi.org/10.1017/S0033291798007697, 2-s2.0-0033016598.
- 32 Liu T.-L., Yang P., Ko C.-H., Yen J.-Y., and Yen C.-F., Association between ADHD symptoms and anxiety symptoms in Taiwanese adolescents, Journal of Attention Disorders. (2014) 18, no. 5, 447–455, https://doi.org/10.1177/1087054712439936, 2-s2.0-84901911804.
- 33 Hartman C. A., Rommelse N., Van der Klugt C. L., Wanders R. B. K., and Timmerman M. E., Stress exposure and the course of ADHD from childhood to young adulthood: comorbid severe emotion dysregulation or mood and anxiety problems, Journal of Clinical Medicine. (2019) 8, no. 11, https://doi.org/10.3390/jcm8111824.
- 34 Öncü B., Öner Ö., Öner P., Erol N., Aysev A., and Canat S., Symptoms defined by parents′ and teachers′ ratings in attention-deficit hyperactivity disorder: changes with age, Canadian Journal of Psychiatry. (2004) 49, no. 7, 487–491, https://doi.org/10.1177/070674370404900711, 2-s2.0-4043123152.
- 35 Gair S. L., Brown H. R., Kang S., Grabell A. S., and Harvey E. A., Early development of comorbidity between symptoms of ADHD and anxiety, Research on Child and Adolescent Psychopathology. (2021) 49, no. 3, 311–323, https://doi.org/10.1007/s10802-020-00724-6, 33404952.
- 36 Ahmann P. A., Waltonen S. J., Theye F. W., Olson K. A., and van Erem A. J., Placebo-controlled evaluation of Ritalin side effects, Pediatrics. (1993) 91, no. 6, 1101–1106, https://doi.org/10.1542/peds.91.6.1101.
- 37 Barkley R. A., McMurray M. B., Edelbrock C. S., and Robbins K., Side effects of metlyiphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation, Pediatrics. (1990) 86, no. 2, 184–192, https://doi.org/10.1542/peds.86.2.184, 2196520.
- 38 Shih H. H., Shang C. Y., and Shur-Fen G. S., Comparative efficacy of methylphenidate and atomoxetine on emotional and behavioral problems in youths with attention-deficit/hyperactivity disorder, Journal of Child and Adolescent Psychopharmacology. (2019) 29, no. 1, 9–19, https://doi.org/10.1089/cap.2018.0076, 2-s2.0-85060531135, 30457349.
- 39 Rapport M. D. and Moffit C., Attention deficit/hyperactivity disorder and methylphenidate: a review of height/weight, cardiovascular, and somatic complaint side effects, Clinical Psychology Review. (2002) 22, no. 8, 1107–1131, https://doi.org/10.1016/S0272-7358(02)00129-0, 2-s2.0-0036837114.
- 40 Jarrett M. A., Wolff J. C., DavisT. E.3rd, Cowart M. J., and Ollendick T. H., Characteristics of children with ADHD and comorbid anxiety, Journal of Attention Disorders. (2016) 20, no. 7, 636–644, https://doi.org/10.1177/1087054712452914, 2-s2.0-84974577263.
- 41 Coughlin C. G., Cohen S. C., Mulqueen J. M., Ferracioli-Oda E., Stuckelman Z. D., and Bloch M. H., Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder, Journal of Child and Adolescent Psychopharmacology. (2015) 25, no. 8, 611–617, https://doi.org/10.1089/cap.2015.0075, 2-s2.0-84945570549.
